HLX301

DRUG2 trials

Sponsors

Shanghai Henlius Biotech

Conditions

Advanced TumorsLocally Advanced or Metastatic Solid TumorsLymphomaMetastatic TumorsNon-small Cell Lung Cancer

Phase 1

HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

Shanghai Henlius BiotechLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer

Start: 2022-05-03End: 2024-02-29Target: 150Updated: 2023-08-08

A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma

Shanghai Henlius BiotechAdvanced Tumors, Lymphoma, Metastatic Tumors

Start: 2022-06-20End: 2024-12-30Target: 30Updated: 2023-08-08

Related Papers

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HLX301, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.

Journal of Clinical Oncology2025-05-28